Juvenile xanthogranuloma

Juvenile xanthogranuloma (JXG) is a benign non-Langerhans cell histiocytic disorder characterized by the accumulation of lipid-laden macrophages (histiocytes) in the skin and occasionally in other organs. It is the most common form of non-Langerhans cell histiocytosis in childhood. JXG typically presents as one or more firm, round, yellowish-orange to reddish-brown papules or nodules on the skin, most commonly on the head, neck, and trunk. Lesions may also appear on the extremities. The condition predominantly affects infants and young children, with most cases appearing within the first year of life, though it can rarely occur in adults. While JXG is most often limited to the skin (cutaneous form), extracutaneous involvement can occur in a minority of cases, affecting the eyes (particularly the iris, which can lead to spontaneous hyphema and glaucoma), central nervous system, liver, spleen, lungs, and other organs. Ocular JXG is the most clinically significant extracutaneous manifestation and requires prompt ophthalmologic evaluation, especially in children with multiple skin lesions. There is a recognized association between JXG and neurofibromatosis type 1 (NF1), and children with both conditions may have an increased risk of developing juvenile myelomonocytic leukemia (JMML), though this association remains under investigation. In most cases, cutaneous JXG is a self-limiting condition that spontaneously regresses over months to years, often leaving only mild skin changes such as slight atrophy or hyperpigmentation. Treatment is generally not required for isolated skin lesions. For extracutaneous disease causing organ dysfunction, treatment options may include surgical excision, systemic or intralesional corticosteroids, and in rare severe cases, chemotherapy. Ocular involvement may be treated with topical or subconjunctival corticosteroids, or surgical intervention if necessary. Regular monitoring by a dermatologist and ophthalmologist is recommended, particularly for young children with multiple lesions.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Juvenile xanthogranuloma